Study of D-2570 in Subjects With Non-Segmental Vitiligo (D2570-206)
A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo
This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.
Eligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase All participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety and efficacy of D-2570 in subjects with non-segmental vitiligo. The study consists of three periods: a screening period (up to 4 weeks), a 24-week double-blind treatment period, and a 24-week extension treatment period, followed by a 4-week safety follow-up period.
During the screening period, written informed consent will be obtained from each subject, and eligibility will be assessed based on predefined inclusion and exclusion criteria. Subjects who meet all eligibility criteria will be stratified according to baseline vitiligo severity (T-VASI <15 or ≥15) and disease activity (active or stable), then randomized in a 1:1:1:1 ratio to one of four treatment groups: D-2570 Group A, D-2570 Group B, D-2570 Group C, or placebo.
During the 24-week double-blind treatment period, subjects will receive once-daily oral study medication. Subjects in Groups A and B will continue the same dose in the subsequent 24-week extension period. Subjects in Group C and the placebo group will be re-randomized in a 1:1 ratio to either Group A or Group B for the extension period, maintaining the blind.
All subjects will attend study visits at protocol-specified time points, including assessments of efficacy (including T-VASI), safety (including adverse events, clinical laboratory tests, vital signs, and physical examinations), and pharmacokinetic evaluations via blood sampling. The study will conclude with an end-of-study (EOS) visit at Week 52, 4 weeks after the last dose of study medication, to collect final safety data. All subjects, investigators, and study site personnel will remain blinded to treatment assignments throughout the study.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: shilin Sha
- Numer telefonu: 15601826678
- E-mail: shilin.sha@inventisbio.com
Lokalizacje studiów
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 201203
- Rekrutacyjny
- Huashan Hospital, Fudan University
-
Kontakt:
- shilin Sha
- Numer telefonu: 15601826678
- E-mail: shilin.sha@inventisbio.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Voluntarily signs informed consent and complies with study procedures.
- Age 18-65 years, male or female.
- Clinical diagnosis of non-segmental vitiligo at screening.
- F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.
- Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.
Exclusion Criteria:
- - Segmental, mixed vitiligo or other concurrent pigmentary/active skin disorders interfering with study assessment.
- Over 33% facial or total vitiligo lesions with leukotrichia.
- Pregnant or breastfeeding females.
- Active, latent or inadequately treated tuberculosis infection.
- Positive HIV, active HBV/HCV infection, or untreated syphilis.
- Current or history of severe herpes infection.
- Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.
- Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.
- Uncontrolled thyroid disease, severe cardiovascular/cerebrovascular disease or other unstable severe systemic disorders.
- Severe psychiatric disease, suicidal ideation, or alcohol/drug abuse within 6 months.
- Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).
- Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.
- Clinically significant abnormal lab results: elevated liver/renal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.
- History of severe drug hypersensitivity or drug-related toxicity.
- Any condition that may impair protocol compliance or study participation per investigator judgment.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: D-2570 Dose 1 (experimental arm 1)
Subjects in this arm will receive oral D-2570 Dose 1 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 1 in the subsequent 24-week extension period.
|
Oral D-2570 Dose 1 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period
|
|
Eksperymentalny: D-2570 Dose 2 (experimental arm 2)
Subjects in this arm will receive oral D-2570 Dose 2 once daily (QD) for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose of D-2570 Dose 2 in the subsequent 24-week extension period
|
Oral D-2570 Dose 2 administered once daily for 24 weeks during the double-blind treatment period.
Eligible subjects may continue the same dose in the 24-week extension period.
|
|
Eksperymentalny: D-2570 Dose 3 (experimental arm 3)
Subjects in this arm will receive oral D-2570 Dose 3 once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral D-2570 Dose 3 administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
|
Komparator placebo: placebo
Subjects in this arm will receive matching placebo once daily (QD) for 24 weeks during the double-blind treatment period.
After 24 weeks, subjects will be re-randomized to either D-2570 Dose 1 or Dose 2 once daily for the extension period.
|
Oral placebo administered once daily for 24 weeks during the double-blind treatment period.
Subjects will be re-randomized to D-2570 Dose 1 or Dose 2 in the extension period.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI)
Ramy czasowe: week24
|
Change rate of facial vitiligo area, measured by F-VASI score, relative to baseline
|
week24
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change and percentage change from baseline in F-VASI
Ramy czasowe: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in facial vitiligo area, measured by F-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving F-VASI50/75/90
Ramy czasowe: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in F-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Change and percentage change from baseline in T-VASI
Ramy czasowe: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Absolute change and percentage change in total vitiligo area, measured by T-VASI score, relative to baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects achieving T-VASI50/75/90
Ramy czasowe: Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
Percentage of subjects with ≥50%, ≥75%, or ≥90% reduction in T-VASI score from baseline.
|
Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48
|
|
Proportion of subjects with F-PhGVA score 0 or 1
Ramy czasowe: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with F-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with T-PhGVA score 0 or 1
Ramy czasowe: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with T-PhGVA score of 0 (clear) or 1 (almost clear).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Proportion of subjects with VNS score 4 or 5
Ramy czasowe: Weeks 8, 16, 24, 32, 40, and 48
|
Percentage of subjects with VNS score of 4 (hardly noticeable) or 5 (not noticeable).
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in DLQI score
Ramy czasowe: Weeks 8, 16, 24, 32, 40, and 48
|
Change in Dermatology Quality of Life Index (DLQI) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Change from baseline in VitiQoL score
Ramy czasowe: Weeks 8, 16, 24, 32, 40, and 48
|
Change in Vitiligo-Specific Quality of Life (VitiQoL) score relative to baseline.
|
Weeks 8, 16, 24, 32, 40, and 48
|
|
Plasma concentrations of D-2570
Ramy czasowe: Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
|
|
Safety of D-2570（AEs）
Ramy czasowe: Through study completion (approximately Week 48)
|
Through study completion (approximately Week 48)
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- D2570-206
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .